Article
Novartis presents latest data on verteporfin for AMD
Researchers working with Novartis Ophthalmics presented data Monday onwet age-related macular degeneration (AMD) and verteporfin (Visudyne) therapyduring a session on AMD.Entitled "Age-Related Macular Degeneration: Photodynamic Therapy,"the session highlighted three papers that focused on verteporfin.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
